Soleno Therapeutics Faces Lawsuit Over Safety Concerns for Prader-Willi Syndrome Drug DCCR.
- Soleno Therapeutics faces a securities class action lawsuit due to misrepresentations about the safety of its drug DCCR (VYKAT™ XR).
- The company's stock price dropped 26% after concerns about serious side effects, including fluid retention, were reported.
- Legal scrutiny raises doubts about DCCR's market viability, impacting investor confidence and potential sales in rare disease treatments.
Soleno Therapeutics Faces Legal Repercussions Over Drug Safety Concerns
Soleno Therapeutics, Inc. is currently embroiled in a securities class action lawsuit, representing investors who purchased the company's common stock between March 26 and November 4, 2025. This legal challenge emerges in the wake of a disappointing report regarding Soleno's hyperphagia treatment drug, DCCR, branded as VYKAT™ XR, which triggered a significant 26% decline in stock price on November 5, 2025. The allegations leveled against Soleno suggest that the company misrepresented the safety and efficacy of DCCR, specifically downplaying serious side effects, including excessive fluid retention, experienced by some clinical trial participants. The report on DCCR, which is aimed at treating a crucial symptom of Prader-Willi Syndrome (PWS), raises apprehensions about the drug's overall market viability and safety for patients.
As legal implications unfold, shareholder rights firm Hagens Berman leads the charge in investigating possible violations of federal securities laws by Soleno. The lawsuit points to the potential hazards related to DCCR, particularly how the company may have understated risks that could have negative impacts on its market reception. Activist short seller Scorpion Capital adds further scrutiny, suggesting that numerous reports of adverse health incidents among children taking VYKAT™ XR may jeopardize both the drug's acceptance by physicians and its future prescription rates. The concerns outlined by Scorpion include alarming cases of hospitalization due to suspected heart failure linked to DCCR use, casting doubt on the prudent marketing of the drug.
Rosen Law Firm also emphasizes the urgency for affected investors to participate in the class action, noting a deadline of May 5, 2026, to file claims. Their involvement underscores the critical need for accurate and transparent reporting from pharmaceutical companies, especially those developing treatments for vulnerable populations like children with PWS. The escalating scrutiny faced by Soleno not only endangers investor confidence but also threatens the therapeutic prospects for families dependent on the company's innovations in this specialized area of healthcare.
In addition to the legal backlash, Soleno's reputation and operational future are at stake. The company, headquartered in Redwood City, California, has focused its efforts on therapies for rare diseases, with DCCR as its one significant commercial product. The ongoing investigations and lawsuits may create obstacles not just for Soleno but for the rare disease pharmaceutical market, which relies heavily on trust and safety standards in clinical development.
The developments around Soleno Therapeutics highlight critical issues in the pharmaceutical industry, where the balance of patient safety, regulatory compliance, and investor transparency must remain paramount to ensure the trust of stakeholders across the board.
